CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Sean A. Mccarthy sold 6,526 shares of the stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $25.01, for a total value of $163,215.26. Following the completion of the transaction, the insider now directly owns 11,169 shares of the company’s stock, valued at $279,336.69. The sale was disclosed in a filing with the SEC, which is available at this link.
CytomX Therapeutics, Inc. (NASDAQ CTMX) traded down $0.53 during mid-day trading on Tuesday, reaching $24.34. The company had a trading volume of 634,500 shares, compared to its average volume of 427,780. CytomX Therapeutics, Inc. has a 12-month low of $10.64 and a 12-month high of $25.21. The firm has a market cap of $961.75 and a PE ratio of -15.50.
A number of brokerages have recently issued reports on CTMX. Cowen reissued an “outperform” rating on shares of CytomX Therapeutics in a report on Thursday, October 5th. Citigroup began coverage on CytomX Therapeutics in a report on Friday. They issued a “buy” rating and a $40.00 target price for the company. BidaskClub raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 15th. ValuEngine cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Zacks Investment Research raised CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $32.78.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.